MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

Targeted therapies designed to exploit specific molecular pathways in aggressive cancers are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as the t(4;11) translocation cause aggressive leukemias that are refractory to conventional treatment. The t(4;11) translocat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Rep
Autori principali: Benito, Juliana M., Godfrey, Laura, Kojima, Kensuke, Hogdal, Leah, Wunderlich, Mark, Geng, Huimin, Marzo, Isabel, Harutyunyan, Karine G., Golfman, Leonard, North, Phillip, Kerry, Jon, Ballabio, Erica, Chonghaile, Triona Ní, Gonzalo, Oscar, Qiu, Yihua, Jeremias, Irmela, Debose, LaKiesha, O’Brien, Eric, Ma, Helen, Zhou, Ping, Jacamo, Rodrigo, Park, Eugene, Coombes, Kevin R., Zhang, Nianxiang, Thomas, Deborah A., O’Brien, Susan, Kantarjian, Hagop M., Leverson, Joel D., Kornblau, Steven M., Andreeff, Michael, Müschen, Markus, Zweidler-McKay, Patrick A., Mulloy, James C., Letai, Anthony, Milne, Thomas A., Konopleva, Marina
Natura: Artigo
Lingua:Inglês
Pubblicazione: Cell Press 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4700051/
https://ncbi.nlm.nih.gov/pubmed/26711339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2015.12.003
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi